Equities research analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings per share (EPS) of ($0.17) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.13). BioCryst Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 6.3%. The firm is expected to issue its next earnings results on Monday, November 6th.
On average, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($0.71) per share for the current year, with EPS estimates ranging from ($0.78) to ($0.61). For the next financial year, analysts anticipate that the company will post earnings of ($0.73) per share, with EPS estimates ranging from ($0.89) to ($0.58). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.02. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The company’s quarterly revenue was down 35.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.22) earnings per share.
A number of brokerages have issued reports on BCRX. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Saturday, May 6th. ValuEngine downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $8.00.
Hedge funds have recently bought and sold shares of the company. Swiss National Bank boosted its stake in BioCryst Pharmaceuticals by 18.7% in the first quarter. Swiss National Bank now owns 114,300 shares of the biotechnology company’s stock worth $960,000 after buying an additional 18,000 shares during the period. Bank of New York Mellon Corp boosted its stake in BioCryst Pharmaceuticals by 6.8% in the first quarter. Bank of New York Mellon Corp now owns 361,289 shares of the biotechnology company’s stock worth $3,035,000 after buying an additional 23,072 shares during the period. UBS Asset Management Americas Inc. purchased a new stake in BioCryst Pharmaceuticals during the first quarter worth approximately $392,000. Emory University purchased a new stake in BioCryst Pharmaceuticals during the first quarter worth approximately $3,153,000. Finally, Trexquant Investment LP boosted its stake in BioCryst Pharmaceuticals by 39.3% in the first quarter. Trexquant Investment LP now owns 50,791 shares of the biotechnology company’s stock worth $427,000 after buying an additional 14,333 shares during the period. Institutional investors and hedge funds own 84.49% of the company’s stock.
BioCryst Pharmaceuticals (NASDAQ BCRX) traded up 5.10% during mid-day trading on Friday, hitting $4.53. The stock had a trading volume of 824,839 shares. BioCryst Pharmaceuticals has a one year low of $3.75 and a one year high of $9.25. The stock’s market cap is $364.34 million. The firm’s 50-day moving average is $5.36 and its 200 day moving average is $6.28.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.